2016-2026年血液學領域的合作與授權協議

讓我們透過 234 個案例研究中有關合作與許可協議的信息，來了解血液學領域合作的趨勢。

《2016-2026 年血液學領域的合作與許可協議》提供了有關血液學領域資產、技術和開發計劃的 234 項合作交易的全面資訊。

血液學領域的合作涵蓋惡性和非惡性疾病，涉及多種治療方法、技術和研發階段。交易結構反映了該領域的科學複雜性、標靶治療和先進治療方法的日益普及，以及針對不同適應症的研發和商業化策略的差異。

本報告將這些趨勢匯總到一個資源中，使用戶能夠了解哪些公司正在合作，哪些血液學機會正在吸引關注，交易是如何構建的，披露了哪些財務條款，以及交易如何根據治療適應症、技術和開發階段而有所不同。

這份報告不只是簡單地列出了交易清單；它結合了全面的市場交易分析和財務基準、主要交易商的信息、詳細的交易記錄以及公開的合約文件。

本報告為血液學領域的業務發展、許可、交易來源和評估、公司策略、研發策略、競爭情報分析以及參與合作的法律團隊提供可操作的資訊和基準資源。

了解血液學領域合作的整體情況。

本報告分析了2016年至2026年血液學領域的交易狀況，內容包括：

• 血液學領域合作的年度趨勢
• 按交易類型分類的交易趨勢
• 產業部門
• 合作關係發展階段
• 技術類型
• 適應症
• 血液學領域最活躍的交易商
• 根據已披露的交易金額，主要交易
• 血液學領域合作活動的趨勢
• 這使用戶能夠確定他們的活動集中在哪些方面，並了解哪些公司、技術、開發階段和治療領域正在吸引合作興趣。
• 血液學領域合夥企業財務狀況基準分析
• 財務條款可能因資產、開發階段、技術、授予的權利以及交易的整體結構而有很大差異。

本報告對已揭露的財務狀況進行了詳細分析，包括以下內容：

• 交易總額
• 預付款
• 里程碑付款
• 版稅率
• 透過分析這些基準背後的具體交易，用戶可以更全面地了解所揭露的經濟數據背後的經濟狀況。
• 這為內部基準測試、機會評估、交易準備和談判提供了一個現實的基準。
• 財務基準只有在結合類似交易的結構和情況進行解讀時，才能發揮其最大效用，而不僅僅將其視為平均值。本報告提供了建構這種背景所需的交易基本資訊。
• 確定血液學領域的關鍵交易撮合者和潛在的未來合作夥伴。
• 本報告列出了在血液學領域合作活動最活躍的公司，並提供交易歷史記錄，以便用戶可以調查其過去的活動。

這使用戶能夠識別以下內容：

• 積極尋求血液學領域機會的公司
• 有潛力的許可和合作研究夥伴
• 我們曾多次在相關血液學適應症方面與其合作的組織。
• 積極參與開發過程的公司
• 對特定技術或治療方法表現出興趣的交易商
• 競爭對手正在推廣相關的外部創新策略
• 對於在血液學領域尋求資產和技術合作夥伴的公司而言，過去的交易歷史可以提供寶貴的見解，了解哪些組織對類似的機會表現出了興趣。
• 比較不同血液疾病適應症和標靶的合作活動。
• 血液學涵蓋了廣泛的惡性和非惡性疾病，每種疾病都有其獨特的科學、臨床和商業性趨勢。
• 本報告按治療適應症和治療標靶分析合作關係，使用戶能夠專注於與特定項目或策略關注事項最相關的交易，而不是僅對整體血液學領域進行基準比較。
• 透過結合技術和發展階段的分析，用戶可以找到更多有意義的類似交易和潛在合作夥伴。
• 了解血液學領域的合約結構
• 本報告包括聯合研究、授權、開發、研發及其他合作交易。

根據交易詳情和資訊披露，用戶可以調查以下方面：

• 授予和保留的權利
• 研發職責
• 授權權
• 獨家版權
• 區域權利
• 智慧財產
• 發展和監管義務
• 製造和供應方面的職責
• 商業化權利
• 金錢補償
• 里程碑和版稅
• 管治
• 合約期限和終止條款
• 這些例子對於考慮血液學領域合作的適當框架將很有用。
• 從實際合約文件中學習
• 本報告提供了公開可取得的有關所選血液學領域交易的基礎合約文件的途徑。

這些合約提供的資訊遠比簡單的標題公告詳細得多，使用戶能夠了解公司如何記錄以下內容：

• 權利範圍
• 發展義務
• 智慧財產
• 獨家版權
• 財務狀況
• 里程碑觸發條件
• 特許權使用費規定
• 商業化權利
• 合約終止及其他談判事項
• 對於準備和談判血液學領域合作研究和許可協議的團隊來說，獲取實際的合約措辭可以深入了解類似交易的實際結構。
• 血液學領域綜合交易目錄
• 本報告收錄了血液學領域 234 項合作研究和許可協議的綜合目錄，為識別相關先例提供了專門的資訊來源。

在以下條件下可以查看交易記錄：

• 公司
• 技術類型
• 治療適應症或標靶
• 合約揭露狀態
• 每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
• 你會向誰推薦這份報告？
• 業務拓展與授權團隊
• 識別類似的血液學相關交易、潛在的未來合作關係以及相關的交易結構。
• 研究與評估團隊
• 我們將根據相關適應症、技術和發展階段，確定哪些公司正在積極探索血液學領域的商機。
• 尋求合作夥伴的生技公司
• 找出對類似血液學相關資產或技術表現出明確興趣的組織。
• 企業策略與研發策略團隊
• 我們將了解競爭對手和潛在合作夥伴如何透過外部創新來建立其血液學產品組合。
• 競爭與市場情報團隊
• 按公司、適應症、目標、開發階段和技術追蹤合作趨勢，以了解不斷變化的策略重點。
• 法律及交易團隊
• 我們將仔細審查公開的合約和以往的合約結構，以幫助您準備和談判交易。
• 將市場範圍內的血液學資訊轉化為公司特有的洞察。
• 符合資格的客戶將收到 Current Partnering 的報告，以及為高階主管量身訂製的合作關係簡報。
• 本簡報將運用血液學領域的交易情報，分析您具體的資產、技術、適應症、目標或合作目標。
• 如有需要，我們可以提供相關的類似交易、潛在的未來合作夥伴、競爭對手的活動、發展階段分析、交易結構、財務基準、忠誠度分析、合約見解以及其他專門為您情況選擇的資訊。
• 請索取樣本或聯絡 Current Partnering 討論報告內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章：引言

第2章：血液學領域交易趨勢

• 血液學領域合作史
• 血液學領域按交易類型分類的合作關係
• 血液學領域特定產業的合作趨勢
• 血液學領域不同發展階段的合作
• 按技術類型分類的血液學領域合作
• 基於治療適應症的血液學領域合作

第3章 血液學領域合夥企業的財務條件

• 已披露血液學領域合作的財務條款
• 血液學領域合作中的大額合約
• 血液學領域合約中的預付款
• 血液學領域合作的里程碑付款
• 血液學領域的專利使用費率

第4章：血液學領域的主要交易與交易商

• 血液學領域合作中最活躍的參與者
• 血液學領域最活躍的交易商名單
• 血液學領域表現最佳的交易

第5章：血液學領域合約文件目錄

• 血液學領域內有合約文件的合作項目。

第6章：血液學治療標靶領域的交易趨勢

• 血液學治療標靶交易
• 交易目錄
• 交易目錄 - 按公司名稱（A-Z）列出的血液學領域交易
• 交易目錄 - 按技術類型分類的血液學領域交易
• 交易類型的定義
• 關於生物製藥研究
• Current Partnering
• Current Agreements
• 理想合作夥伴近期報告標題

Understand the hematology partnering landscape using intelligence from 234 real-world collaboration and licensing deals.

Hematology Collaboration and Licensing Deals 2016-2026 provides comprehensive intelligence on 234 partnering deals involving hematology assets, technologies and development programs.

Hematology partnering spans both malignant and non-malignant disorders and encompasses a diverse range of therapeutic approaches, technologies and stages of development. Deal structures reflect the scientific complexity of the field, the increasing use of targeted and advanced therapeutic approaches, and differing development and commercialization strategies across individual indications.

The report brings this activity together in one resource, enabling users to understand who is partnering, which hematology opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in hematology partnering.

Understand the hematology partnering landscape

The report analyzes hematology dealmaking from 2016 to 2026, including:

• Trends in hematology partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• Therapeutic indication
• Most active hematology dealmakers
• Leading deals by disclosed value
• How hematology partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark hematology deal financials
• Financial terms can vary considerably according to the asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading hematology dealmakers and prospective partners
• The report identifies the most active companies in hematology partnering and provides transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking hematology opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in relevant hematology indications
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in particular technologies or therapeutic approaches
• Competitors pursuing related external innovation strategies
• For companies seeking to partner a hematology asset or technology, previous transaction activity can provide useful evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across hematology indications and targets
• Hematology covers a range of malignant and non-malignant disorders with differing scientific, clinical and commercial dynamics.
• The report analyzes partnering by therapeutic indication and therapeutic target, enabling users to move beyond broad hematology benchmarks and focus on transactions most relevant to a particular program or strategic interest.
• Combined with analysis by technology and development stage, this helps users identify more meaningful comparable transactions and prospective partners.
• Understand how hematology agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for a hematology partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected hematology transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating a hematology collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive hematology deal directory
• The report includes a comprehensive directory of 234 hematology collaboration and licensing deals, providing a focused resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication or target
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable hematology transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking hematology opportunities across relevant indications, technologies and development stages.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable hematology assets and technologies.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building hematology portfolios through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, target, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide hematology intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying hematology deal intelligence to the customer's own asset, technology, indication, target or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in hematology dealmaking

• 2.1. Introduction
• 2.2. Hematology partnering over the years
• 2.3. Hematology partnering by deal type
• 2.4. Hematology partnering by industry sector
• 2.5. Hematology partnering by stage of development
• 2.6. Hematology partnering by technology type
• 2.7. Hematology partnering by therapeutic indication

Chapter 3 - Financial deal terms for hematology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for hematology partnering
• 3.3. Hematology partnering headline values
• 3.4. Hematology deal upfront payments
• 3.5. Hematology deal milestone payments
• 3.6. Hematology royalty rates

Chapter 4 - Leading hematology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in hematology partnering
• 4.3. List of most active dealmakers in hematology
• 4.4. Top hematology deals by value

Chapter 5 - Hematology contract document directory

• 5.1. Introduction
• 5.2. Hematology partnering deals where contract document available

Chapter 6 - Hematology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by hematology therapeutic target
• Deal directory
• Deal directory - Hematology deals by company A-Z
• Deal directory - Hematology deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Hematology partnering since 2016
• Figure 2: Hematology partnering by deal type since 2016
• Figure 3: Hematology partnering by industry sector since 2016
• Figure 4: Hematology partnering by stage of development since 2016
• Figure 5: Hematology partnering by technology type since 2016
• Figure 6: Hematology partnering by indication since 2016
• Figure 7: Hematology deals with a headline value
• Figure 8: Hematology deals with upfront payment values
• Figure 9: Hematology deals with milestone payment
• Figure 10: Hematology deals with royalty rates
• Figure 11: Active hematology dealmaking activity since 2016
• Figure 12: Top hematology deals by value since 2016